MetaVia Inc. announced that all active patients in Part 3 of its Phase 1 clinical trial for DA-1726, an obesity treatment, have completed dose titration and are receiving target doses of 48 mg and 64 mg. Topline data from the trial is expected to be released in the fourth quarter of 2026. MetaVia Inc. is a biotechnology company developing clinical-stage drug candidates for metabolic diseases.
